Chemoprevention of Colorectal Cancer: Ready for Routine Use?

  • Nadir Arber
  • Bernard Levin
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 166)


In the third millennium, preventive medicine is becoming a cornerstone in our concept of health. Colorectal cancer (CRC) prevention, in particular, has become an important goal for health providers, physicians and the general public. CRC fits the criteria of a disease suitable for chemopreventive interventions. It is a prevalent disease that is associated with considerable mortality and morbidity rates, with more than 1,000,000 new cases and 500,000 deaths expected, worldwide, in 2004. CRC has a natural history of transition from precursor to malignant lesion that spans, on average, 15-20 years, providing a window of opportunity for effective interventions and prevention. A pre-malignant precursor lesion (i.e.adenoma) usually precedes cancer, and helps to identify a subset of the population that is at increased risk of harbouring and developing cancer. Science and technology have evolved to a point where we are able to use our knowledge of cancer biology to identify individuals at risk and interrupt the process of malignant transformation at the level of the pre-cancerous lesion. Recent progress in molecular biology and pharmacology enhances the likelihood that cancer prevention will increasingly rely on chemoprevention. Chemoprevention, a new emerging science, means the use of agents to inhibit, delay or reverse carcinogenesis. Recent observations suggest a number of potential targets for chemoprevention. Many agents have potential benefit but only modest chemopreventive efficacy in clinical trials. There is much evidence suggesting an inverse relationship between aspirin or non-steroidal anti-inflammatory drug (NSAID) consumption and CRC incidence and mortality. However, NSAID consumption is not problem-free; 1997 data show 107,000 hospitalisations and 16,500 deaths due to NSAID consumption in the U.S. alone. Therefore, although chemoprevention of CRC is already possible, drugs that have more acceptable side-effect profiles than the currently available NSAIDs are required. Cyclo-oxygenase (COX)-2 specific inhibitors, which have an improved safety profile compared to traditional NSAIDs that inhibit both the COX-1 and COX-2 enzymes, seem to be well-suited drug candidates for CRC prevention. The inhibition of the growth of pre-cancerous and cancerous cells without affecting normal cells is the ultimate aim of cancer treatment and is of particular importance in chemoprevention studies, which may be long term in nature, involving healthy subjects and minimal toxicity. Cancer prevention is certain to be a significant focus of research and intervention in the coming years, propelled by the realisation that we will be able to identify both individuals susceptible to specific cancers as well as the molecular targets that can alter or stop the carcinogenesis process. Pharmacology and genetics are collaborating to develop new chemoprevention agents designed to affect molecular targets linked to specific pre-malignant or predisposing conditions.


Colorectal Cancer Familial Adenomatous Polyposis Colorectal Adenoma Colorectal Neoplasia Familial Adenomatous Polyposis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cantor D (1993) Cancer. In: Bynum WF, Porter R (eds) Companion encyclopedia of the history of medicine. Routledge, London, p 552Google Scholar
  2. 2.
    Tattersall MHN, Thomas H (1999) Recent advances: oncology. BMJ 318:445–448PubMedGoogle Scholar
  3. 3.
    Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52:23–47PubMedCrossRefGoogle Scholar
  4. 4.
    American Cancer Society (1998) Cancer facts and figures. American Cancer Society, AtlantaGoogle Scholar
  5. 5.
    Walsh J, Terdiman J (2003) Colorectal cancer screening. JAMA 289:1288–1296PubMedGoogle Scholar
  6. 6.
    Keighley MRB (2003) Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 18:7–30PubMedGoogle Scholar
  7. 7.
    Weir HK, Thun MJ, Hankey BF, et al (2003) Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95:1276–1299PubMedGoogle Scholar
  8. 8.
    Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795–801PubMedCrossRefGoogle Scholar
  9. 9.
    Thun MJ (1996) NSAIDs use and decrease risk of gastrointestinal cancers. Gastroenterol. Gastroenterol Clin North Am 25:333–348Google Scholar
  10. 10.
    Kelloff G (1996) Chemoprevention of colorectal cancer. In: Young G, Rozen P, Levin B (eds) Prevention and early detection of colorectal cancer. WB Saunders, London, pp 116–139Google Scholar
  11. 11.
    Boolbol SK, Dannenberg AJ, Chadurn A, et al (1996) Cyclooxygenase-2 over expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556–2560PubMedGoogle Scholar
  12. 12.
    Mahmoud N, Dannenberg A, Mestre J, et al (1998) Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 124:225–231PubMedGoogle Scholar
  13. 13.
    Jacoby RF, Marshall DJ, Newton MA, et al (1996) Chemoprevention of spontaneous intestinal adenomas in the APC-Min mouse by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56:710–714PubMedGoogle Scholar
  14. 14.
    Oshima M, Murai N, Kargman S, et al (2001) Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61:1733–1740PubMedGoogle Scholar
  15. 15.
    Oshima M, Dinchuk JE, Kargman SL, et al (1996) Suppression of intestinal polyposis in APC (716) knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809PubMedCrossRefGoogle Scholar
  16. 16.
    Moorghen M, Ince P, Finney KJ, et al (1988) A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol 156:341–347PubMedCrossRefGoogle Scholar
  17. 17.
    Skinner SA, Penney AG, O’Brien PE (1991) Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 126:1094–1096PubMedGoogle Scholar
  18. 18.
    Pollard M, Luckert PH (1981) Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 214:558–559PubMedGoogle Scholar
  19. 19.
    Torrance CJ, Jackson PE, Montgomery E, et al (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024–1028PubMedGoogle Scholar
  20. 20.
    Giardiello FM, Hamilton SR, Krush AJ, et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316PubMedCrossRefGoogle Scholar
  21. 21.
    Labayle D, Fischer D, Vielh P, et al (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639PubMedGoogle Scholar
  22. 22.
    Nugent K, Farmer K, Spigelman A, et al (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80:1618–1619PubMedGoogle Scholar
  23. 23.
    Kinzler KW, Nilbert MC, Su LK, et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253:661–665PubMedGoogle Scholar
  24. 24.
    Waddell WR, Ganser GF, Cerise EJ, Loughry RW (1989) Sulindac for polyposis of the colon. Am J Surg 157:175–179PubMedCrossRefGoogle Scholar
  25. 25.
    Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952PubMedCrossRefGoogle Scholar
  26. 26.
    Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber N (2003) Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 48:1998–2002PubMedCrossRefGoogle Scholar
  27. 27.
    Giovannucci E, Egan KM, Hunter DJ, et al (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609–614PubMedCrossRefGoogle Scholar
  28. 28.
    Thun MJ (1996) NSAIDs use and decrease risk of gastrointestinal cancers. Gastroenterol Clin North Am 25:333–347PubMedCrossRefGoogle Scholar
  29. 29.
    Arber N (2000) Do NSAIDs prevent colorectal cancer? Can J Gastroenterol 14:299–307PubMedGoogle Scholar
  30. 30.
    DuBois RN, Giardiello FM, Smalley WE (1996) Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 25:773–791PubMedGoogle Scholar
  31. 31.
    Strate LL, Orav EJ, Syngal S (2003) Early predictors of severity in acute lower intestinal tract bleeding. Arch Intern Med 163:838–843PubMedCrossRefGoogle Scholar
  32. 32.
    Derry S, Loke YK (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321:1183–1187PubMedCrossRefGoogle Scholar
  33. 33.
    Silverstein FE, Faich G, Goldstein JL, et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247–1255PubMedCrossRefGoogle Scholar
  34. 34.
    Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888–1899PubMedCrossRefGoogle Scholar
  35. 35.
    Jones D, Carlton D, McIntyre T, et al (1993) Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 268:9049–9054PubMedGoogle Scholar
  36. 36.
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188PubMedGoogle Scholar
  37. 37.
    Masferrer JL, Zweifel BS, Manning PT, et al (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is anti inflammatory and non ulcerogenic. Proc Natl Acad Sci U S A 91:3228–3232PubMedGoogle Scholar
  38. 39.
    Bombardier C, Laine L, Reicin A, et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J MedGoogle Scholar
  39. 40.
    Reddy BS, Rao CV, Seibert K (1996) Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56:4566–4571PubMedGoogle Scholar
  40. 41.
    Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, Taketo MM, Evans JF (2001) Chemoprevention of intestinal polyposis in the Apc delta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61:1733–1740PubMedGoogle Scholar
  41. 42.
    Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040–5044PubMedGoogle Scholar
  42. 43.
    Tsujii M, Kawano S, Tsuji S, et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRefGoogle Scholar
  43. 44.
    Averbuch M, Kazanov D, Pick M, Strier L, Dvory-Sobol H, Deutsch V, Halpern Z, Arber N (2002) Rofecoxib (MK-966) does not inhibit the growth of transformed cells in vitro. Gastrointest Oncol 4:71–75Google Scholar
  44. 45.
    Kazanov D, Dvory-Sobol H, Pick M, Liberman E, Strier L, Choen-Noyman E, Deutsch V, Kunik T, Arber N (2004) Celecoxib but not rofecoxib inhibits the growth of trans-formed cells in vitro. Clin Cancer Res 10:267–271PubMedGoogle Scholar
  45. 46.
    Rahme E, Barkun AN, Toubouti Y, Bardou M (2003) The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125:404–412PubMedCrossRefGoogle Scholar
  46. 47.
    Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95:681–686PubMedGoogle Scholar
  47. 48.
    Hall PA, Coates PJ, Ansari B, Hopwood D (1994) Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 107:3569–3577PubMedGoogle Scholar
  48. 49.
    Bedi A, Pasricha PJ, Akhtar AJ, et al (1995) Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55:1811–1816PubMedGoogle Scholar
  49. 50.
    Boolbol SK, Dannenberg AJ, Chadurn A, et al (1996) Cyclooxygenase-2 over expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556–2560PubMedGoogle Scholar
  50. 51.
    Yang VW, Shields JM, Hamilton SR, et al (1998) Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 58:1750–1753PubMedGoogle Scholar
  51. 52.
    Williams CS, Luongo C, Radhika A, et al (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111:1134–1140PubMedCrossRefGoogle Scholar
  52. 53.
    DuBois RN, Radhika A, Reddy BS, Entingh AJ (1996) Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 111:1259–1262Google Scholar
  53. 54.
    Fujita T, Matsui M, Takaku K, et al (1998) Size-and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 58:4823–4826PubMedGoogle Scholar
  54. 55.
    Tsujii M, Dubois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493–501PubMedCrossRefGoogle Scholar
  55. 56.
    Mei JM, Hord NG, Winterstein DF, et al (1999) Differential expression of prostaglandin endoperoxide H synthase-2 and formation of activated beta-catenin-LEF-1 transcription complex in mouse colonic epithelial cells contrasting in APC. Carcinogenesis 20:737–740PubMedCrossRefGoogle Scholar
  56. 57.
    Piazza GA, Alberts DS, Hixson LJ, et al (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57:2909–2915PubMedGoogle Scholar
  57. 58.
    Hanif R, Pittas A, Feng Y, et al (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52:237–245PubMedCrossRefGoogle Scholar
  58. 59.
    Yamamoto Y, Yin MJ, Lin KM, Gaynor RB (1999) Sulindac inhibits activation of the NFκB pathway. J Biol Chem 274:27307–27314PubMedGoogle Scholar
  59. 60.
    Gupta RA, Tan J, Krause WF, et al (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 97:13275–13280PubMedCrossRefGoogle Scholar
  60. 61.
    He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335–345PubMedCrossRefGoogle Scholar
  61. 62.
    Janne P, Mayer R (2000) Chemoprevention of colorectal cancer. N Engl J Med 342:1960–1968PubMedCrossRefGoogle Scholar
  62. 63.
    Hawk ET, Limburg PJ, Viner JL (2002) Epidemiology and prevention of colorectal cancer. Surg Clin North Am 82:905–941PubMedCrossRefGoogle Scholar
  63. 64.
    Hawk ET, Viner JL, Umar A (2003) Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Prog Exp Tumor Res 37:210–242PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Nadir Arber
    • 1
  • Bernard Levin
    • 2
  1. 1.Department of Cancer PreventionTel-Aviv Medical CenterTel-AvivIsrael
  2. 2.Division of Cancer Prevention, U.T. MD Anderson Cancer CenterHoustonUSA

Personalised recommendations